EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Senhwa Biosciences's enterprise value is NT$2,187.31 Mil.
Senhwa Biosciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was NT$1.00 Mil. Therefore, Senhwa Biosciences's EV-to-Revenue for today is 2,187.31.
The historical rank and industry rank for Senhwa Biosciences's EV-to-Revenue or its related term are showing as below:
ROCO:6492'
s EV-to-Revenue Range Over the Past 10 Years
Min: 1928.69 Med: 9644.86 Max: 103845.13
Current: 2187.31
During the past 13 years, the highest EV-to-Revenue of Senhwa Biosciences was 103845.13. The lowest was 1928.69. And the median was 9644.86.
ROCO:6492's EV-to-Revenue is ranked worse than 96.98% of 995
companies
in the Biotechnology industry
Industry Median: 7.17
vs ROCO:6492: 2187.31
The historical data trend for Senhwa Biosciences's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Senhwa Biosciences's EV-to-Revenue
For the Biotechnology subindustry, Senhwa Biosciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Senhwa Biosciences's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Senhwa Biosciences's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Senhwa Biosciences's EV-to-Revenue falls into.
Senhwa Biosciences's current Enterprise Value is NT$2,187.31 Mil.
Senhwa Biosciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$1.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Senhwa Biosciences's share price for today is NT$35.15.
Senhwa Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Senhwa Biosciences EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Senhwa Biosciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Senhwa Biosciences Inc is engaged in the development of new drugs and special pharmaceutical ingredients focusing on human efficacy. The company's product pipeline includes Pidnarulex (CX-5461), Silmitasertib (CX-4945), and Silmitasertib (for Moderate Covid-19). All of its revenue comes from Taiwan.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ROCO:6492 has been successfully added to your 